NCT01253681 - Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

January 31, 2015

Conditions

CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Interventions

DRUG

AMG 386, paclitaxel and carboplatin

15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.

Trial Locations (8)

1000

Research Site, Brussels

1200

Research Site, Brussels

3000

Research Site, Leuven

3011

Research Site, Footscray

3052

Research Site, Parkville

3144

Research Site, Malvern

28040

Research Site, Madrid

08035

Research Site, Barcelona